Bristol-Myers Squibb Co.

Most Recent

  • uploads///BMY
    Company & Industry Overviews

    How Bristol-Myers Squibb’s Key Products Performed in 1Q18

    Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Non Investment Grade Bonds Yields Spreads
    Company & Industry Overviews

    How Did US Financial Markets Fare in October 2015?

    The S&P 500 index, tracked by the SPDR S&P 500 ETF (SPY) and the iShares Core S&P 500 ETF (IVV), rose 8.3% in October.

    By David Ashworth
  • uploads///Chart  AR
    Earnings Report

    Analysts’ Ratings and Recommendations for Johnson & Johnson

    JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.

    By Mike Benson
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Analysts
    Company & Industry Overviews

    How Analysts View Johnson & Johnson in October

    On October 18, Johnson & Johnson announced a fourth-quarter cash dividend of $0.90 per share for its common stock.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///ISM
    Macroeconomic Analysis

    Expanding Service Sector Gives Relief to Economy in September

    With manufacturing slowing, a reading of the Non-Manufacturing Index at an above-neutral level (56.9) may provide some relief to the US economy, which is highly dependent on the service sector for its economic growth.

    By Lara Sheldon
  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 3Q17 Revenue Estimates Could Reveal Growth

    Johnson & Johnson’s (JNJ) revenues are expected to report 8.3% growth to $19.3 billion during 3Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Avastin
    Company & Industry Overviews

    A Performance Update for Roche’s Avastin in H2 2018

    In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy.

    By Daniel Collins
  • uploads///blood _
    Healthcare

    Johnson & Johnson Stock on March 29, 2018

    Although Johnson & Johnson stock has fallen ~3.5% in the last month, its stock has risen ~1.4% in the last year.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    Squire Study Supports Portrazza’s Approval

    The FDA approved Portrazza for the treatment of squamous NSCLC based on the results of a phase III study named Squire.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///health
    Company & Industry Overviews

    Johnson & Johnson’s Valuation in February 2018

    Johnson & Johnson (JNJ) reported revenues of $20.2 billion in 4Q17, an 11.5% growth compared to 4Q16.

    By Mike Benson
  • uploads///GILD
    Company & Industry Overviews

    What Does Gilead Sciences’ Bottom-Line Trend Indicate?

    Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter.

    By Kenneth Smith
  • uploads///Nektar Revenue Trend
    Company & Industry Overviews

    A Look at Nektar Therapeutics’ Financial Performance

    Diversified revenue streams Nektar Therapeutics’ (NKTR) total revenue includes product sales, royalty revenue, non-cash revenue related to the sale of future royalties, and license and collaboration revenue. Nektar had product sales of $4.4 million in 3Q17, compared with $144.7 million in 3Q16. Between 3Q16 and 3Q17, its royalty revenue rose from $5.5 million to $9.3 million, and its license […]

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb Continues Revenue Growth in 3Q16

    Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Bristol-Myers Capitalizes on Japanese Markets for Its Cardio Drug

    Based on prescriptions issued by cardiologists, Bristol-Myers Squibb’s and Pfizer’s Eliquis is considered the top-ranking novel anticoagulant in the US.

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Analyzing XLV’s Trend on Different Moving Averages

    On June 14, XLV closed at $71.32. It was trading above its 20-day, 50-day, and 100-day moving averages. XLV’s 20-day moving average was $71.05.

    By Peter Neil
  • uploads///Chart
    Earnings Report

    Analysts’ Estimates and Recommendations for Allergan on July 19

    Analysts expect Allergan’s second-quarter revenue to fall ~2.5% to $3.9 million compared to its revenue of $4.0 million in the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s International Business Segment

    Allergan’s International Business segment reported revenue of $864 million during the first quarter.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///Chart  RevEPS
    Company & Industry Overviews

    Eli Lilly’s Valuation in December 2017

    Eli Lilly (LLY) surpassed analysts’ estimates for EPS and revenues and reported EPS of $1.05 on revenues of $5.7 billion in 3Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///pills _
    Earnings Report

    How AbbVie Fared in Q2 2018

    Driven by growth in Humira, Imbruvica, and Mavyret sales, AbbVie (ABBV) delivered strong Q2 2018 results on July 27.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///PE
    Company & Industry Overviews

    Understanding the Recent Fall in Bristol-Myers Squibb’s Valuation

    On October 4, 2016, Bristol-Myers Squibb (BMY) was trading at a forward PE (price-to-earnings) multiple of 16.8x. With products Opdivo and Yervoy, the company leads the immuno-oncology space.

    By Jillian Dabney
  • uploads///Analysts Rating
    Company & Industry Overviews

    What Analysts Recommend for Bristol-Myers Squibb in November 2017

    23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Novartis or BMY: Who’s Expected to Report Faster EPS Growth?

    In its fourth-quarter earnings investor presentation, Novartis (NVS) provided operating income guidance for two scenarios.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for AstraZeneca in June 2017

    In 1Q17, AstraZeneca (AZN) reported revenues close to $5.4 billion, which is a fall of around 12.0% on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    Merck’s Gardasil and Other Human Vaccines in 3Q17

    Merck & Co.’s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    AstraZeneca’s Other Products in 3Q16

    With lower sales from blockbuster drugs Nexium and Seroquel, the contribution of AstraZeneca’s (AZN) Other segment fell to ~21.2% in 3Q16.

    By Mike Benson
  • uploads///tOP
    Company & Industry Overviews

    Incyte Was the S&P 500’s Top Gainer on May 18

    Incyte rose to one-month high price levels on May 18. Incyte opened higher on Thursday due to positive results from its lung cancer drug.

    By Val Kensington
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Post-1Q18 Valuation

    In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.

    By Mike Benson
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • uploads///medic _
    Company & Industry Overviews

    Analyzing Merck’s Revenue in 1Q18

    Merck (MRK), one of the largest pharmaceutical companies worldwide, reported its 1Q18 results on May 1.

    By Mike Benson
  • uploads///Chart  MRK
    Company & Industry Overviews

    How Merck & Co. Stock Performed in 1Q18

    Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.

    By Mike Benson
  • uploads///core business
    Company & Industry Overviews

    A Close Look at Valeant’s Core Business

    Valeant’s (VRX) core business includes its dermatology and consumer franchise business and the acquired Bausch + Lomb and Salix Pharmaceuticals businesses.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Animal Health Segment Did in 1Q18

    In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.

    By Mike Benson
  • uploads///reent wins
    Company & Industry Overviews

    Inside Bristol’s Key to Success: Multiple Labels for Opdivo

    Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.

    By Jillian Dabney
  • uploads///expenses
    Company & Industry Overviews

    Gilead Sciences Focuses on a Strong Inorganic Growth Strategy

    Gilead Sciences witnessed falling revenues in the past few quarters. Its growth is expected to be revived through new products and mergers and acquisitions.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Biogen Pursuing Investigational Candidates in Alzheimer’s Disease

    Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

    By Margaret Patrick
  • uploads///pill _
    Earnings Report

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 2Q16 Estimates: Other Segments

    Bristol-Myers Squibb’s (BMY) neuroscience segment is represented by the drug Abilify, while its immuno-science segment is represented by the drug Orencia.

    By Mike Benson
  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Pfizer Expands Its Investment Portfolio through Pfizer Ventures

    On June 6, Pfizer announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Recent Commercial and Product Developments

    Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.

    By Mike Benson
  • uploads///GILD oversold
    Company & Industry Overviews

    Is Gilead Sciences Stock Oversold?

    When compared with its estimated $30.2 billion total revenue for 2016, Gilead Sciences’s (GILD) $99 billion market capitalization on November 23 seemed to be at a greater discount. GILD had a forward PE ratio of ~7.0x against its peers’ average PE of ~12.1x.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Why Have Novartis’s Valuation Multiples Fallen?

    Despite patent expiries worth $2.4 billion, Novartis (NVS) managed to report a flat revenue performance in 2016.

    By Margaret Patrick
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Bristol-Myers Squibb’s Other Segments

    Sales from Bristol-Myers Squibb’s Neuroscience segment declined by 94% in 1Q16. Sales from the Immunoscience segment improved by ~18.7% in 1Q16 over 1Q15.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017

    AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///lung cancer
    Company & Industry Overviews

    Why Is Lung Cancer so Attractive to Bristol, Merck, and Roche?

    Bristol-Myers Squibb’s (BMY) Opdivo’s will now share the second-line lung cancer therapy market with Roche’s Tecentriq, along with Merck’s Keytruda.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s 1Q18 Profitability

    Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca Is Taking Steps to Improve Its Position in Oncology

    During the last quarter, the oncology segment’s contribution to AstraZeneca (AZN) increased to over 15%. AZN’s key products for oncology are Zoladex, Faslodex, Iressa, and the new drug Tagrisso.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    New Indications May Be Big Opportunity for AbbVie’s Imbruvica

    On September 26, 2016, AbbVie (ABBV) said it has submitted an application to the FDA for Imbruvica as a treatment for previously treated patients with marginal zone lymphoma.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///Chart  Other
    Earnings Report

    A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

    Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

    By Mike Benson
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis Focuses on Portfolio Prioritization to Boost Profitability

    To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016

    On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

    By Margaret Patrick
  • uploads///syringe _
    Earnings Report

    Merck & Co.’s 1Q18 Earnings: Revenues up 6%

    Merck & Co. beat Wall Street analysts’ estimates for earnings per share (or EPS) today but missed analysts’ estimates for revenues.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///revue ee
    Earnings Report

    BioMarin’s Disappointing 3Q16 Earnings

    BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///people _
    Company & Industry Overviews

    Sage’s Brexanolone IV: FDA Grants Priority Review

    On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.

    By Mike Benson
  • uploads///PD L avelumab
    Company & Industry Overviews

    Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space

    Pfizer plans to use avelumab, a PD-L1 (programmed death-ligand 1) class immuno-oncology product, as a backbone therapy in its immuno-oncology programs.

    By Jillian Dabney
  • uploads///NKTR
    Company & Industry Overviews

    Wall Street Is Still Positive on Nektar’s Immuno-Oncology Drug

    Nektar Therapeutics reported its biggest fall of ~42% on June 4 after the company reported preliminary results for its phase one and phase two trials for the company’s IO (immuno-oncology) candidate

    By Sarah Collins
  • uploads///Virology
    Company & Industry Overviews

    How Merck’s Zepatier and Isentress Are Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    A Look at Pfizer’s Revenue Trends

    Pfizer (PFE) reports revenue in two business segments: Innovative Health and Essential Health.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales

    Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///HCV challenges
    Company & Industry Overviews

    Could There Be a Steep Fall for Gilead Sciences’s HCV Franchise?

    With three products—Sovaldi, Harvoni, and Epclusa—in its arsenal, Gilead Sciences (GILD) dominates the HCV (hepatitis C virus) market.

    By Jillian Dabney
  • uploads///Chart  BMY
    Company & Industry Overviews

    How Bristol-Myers Squibb Stock Performed in 1Q18

    Bristol-Myers Squibb stock has fallen ~1.6% in 1Q18, and its stock has fallen ~0.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Innovative Medicines Segment

    Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: Innovative Medicines Segment

    The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy

    The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

    By Margaret Patrick
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.